Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability
Table 7
(a) Response Surface Linear Model for particle size (). (b) Response Surface Linear Model for PDI ( = 0.0007). (c) Response Surface Quadratic Model for %entrapment ( = 0.0007).
(a)
Response 1—PS (particle size) ANOVA for Response Surface Linear Model Analysis of Variance table (partial sum of squares—Type III)
Source
Sum of squares
df
Mean square
value
value Prob >
Model
19114.42
2
9557.21
73.31
<0.0001
Significant
-
4913.48
1
4913.48
37.69
0.0003
Significant
-
14200.94
1
14200.94
108.93
<0.0001
Significant
Residual
1042.95
8
130.37
—
—
—
Lack of fit
1024.26
6
170.71
18.27
0.0528
Not significant
Pure error
18.69
2
9.34
—
—
—
Cor total
20157.37
10
—
—
—
—
(b)
Response 2—PDI (Poly Dispersity Index) ANOVA for Response Surface Linear Model Analysis of Variance table (partial sum of squares—Type III)
Source
Sum of squares
df
Mean square
value
value Prob >
Model
2
20.94
0.0007
Significant
—amt. of drug
1
4.80
0.0598
Not significant
—conc. of surf.
1
37.08
0.0003
Significant
Residual
8
—
—
—
Lack of fit
6
5.39
0.1648
Not significant
Pure error
2
—
—
—
Cor total
10
—
—
—
—
(c)
Response 3—EE (Entrapment Efficiency) ANOVA for Response Surface Quadratic Model Analysis of Variance table (partial sum of squares—Type III)
